November 6, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix Completes Rolling Submission of New Drug Application
to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
TOKYO, Japan, November 6, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") today announced that Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") announced
on November 5, 2020 (EST) that Chimerix has completed the rolling submission of its New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of brincidofovir(BCV) for the indication of smallpox. SymBio, pursuant to a license agreement with Chimerix enteredinto on September 30, 2019, obtained the exclusive worldwide rights to develop, manufacture, andcommercialize BCV in all human indications, excluding the prevention and treatment of orthopox
infections (which includes smallpox and monkeypox), and SymBio is preparing to initiate a global
study of BCV targeting adenovirus (AdV) infections occurring after hematopoietic stem celltransplantation.
Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoingcollaboration and funding provided by the Biomedical Advanced Research and Development
Authority (BARDA), part of the U.S. Department of Health and Human Services. For more
information, please see Chimerix’s website: https://ir.chimerix.com/press-releases
Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: “Chimerix’scompletion of the submission of the New Drug Application (NDA) for oral brincidofovir under the US
FDA's rolling submission program is a major step forward for SymBio as well. Physicians in Europeand the United States have high expectations for brincidofovir, and we look forward to Chimerix
receiving early approval of the oral formulation for the treatment of smallpox in the United States.”1

About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. Its two clinical-stage development programs are dociparstat
sodium (DSTAT) and brincidofovir (BCV).
BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For
further information, please visit the Chimerix website, www.chimerix.com.
About the Global License Agreement for Brincidofovir
SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters:Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of theagreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, andcommercialize BCV in all human indications, excluding the prevention and treatment of smallpox.
For further information, please see the SymBio’s press release dated October 1, 2019,https://www.symbiopharma.com/news/20191001.pdf
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called
SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medical
needs.

2